Evidence map›Paper›PMID 30933997›Full record

ArticlePloS one2019

Cost and operational impact of promoting upfront GeneXpert MTB/RIF test referrals for presumptive pediatric tuberculosis patients in India.

Sanjay Sarin, Sophie Huddart, Neeraj Raizada, Debadutta Parija, Aakshi Kalra, Raghuram Rao, Virender Singh Salhotra, Sunil D Khaparde, Catharina Boehme, Claudia M Denkinger and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Number needed to screen for TB in clinical, structural or occupational risk groups.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Pooled it
  2. Article
  3. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Sanjay SarinFoundation for Innovative New Diagnostics, New Delhi, India.
Sophie HuddartDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.ORCID 0000-0001-6425-3371
Neeraj RaizadaFoundation for Innovative New Diagnostics, New Delhi, India.
Debadutta ParijaFoundation for Innovative New Diagnostics, New Delhi, India.
Aakshi KalraFoundation for Innovative New Diagnostics, New Delhi, India.
Raghuram RaoCentral TB Division, Government of India, New Delhi, India.
Virender Singh SalhotraCentral TB Division, Government of India, New Delhi, India.
Sunil D KhapardeCentral TB Division, Government of India, New Delhi, India.
Catharina BoehmeFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Claudia M DenkingerFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Hojoon SohnJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Government of India · INFIND · CHJohns Hopkins University · USMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOutreach and promotion programs are essential to ensuring uptake of new public health interventions and guidelines. We assessed the costs and operation dynamics of outreach and promotion efforts for up front Xpert MTB/RIF (Xpert) testing for pediatric presumptive tuberculosis (TB) patients in four major Indian cities.

methodsXpert test costs were assessed as weighted average per-test costs based on the daily workload dynamics matched by test volume specific Xpert unit cost at each study site. Costs of outreach programs to recruit health providers to refer pediatric patients for Xpert testing were assessed as cost per referral for each quarter based on total program costs and referral data. All costs were assessed in the health service provider's perspective and expressed in 2015 USD.

resultsWeighted average per-test costs ranged from $14.71 to $17.81 at the four laboratories assessed. Differences between laboratories were associated with unused testing capacity and/or frequencies of overtime work to cope with increasing demand and same-day testing requirements. Outreach activities generated between 825 and 2,065 Xpert testing referrals on average each quarter across the four study sites, translating into $0.63 to $2.55 per patient referred. Overall outreach costs per referral decreased with time, stabilizing at an average cost of $1.10, and demonstrated a clear association with increased referrals.

conclusionsXpert test and outreach program costs within and across study sites were mainly driven by the dynamics of Xpert testing demand resulting from the combined outreach activities. However, these increases in demand required considerable overtime work resulting in additional costs and operational challenges at the study laboratories. Therefore, careful laboratory operational adjustment should be evaluated at target areas in parallel to the anticipated demand from the Xpert referral outreach program scale-up in other Indian regions.

Indexed as

Genetic TestingHealth Care CostsMolecular Diagnostic TechniquesWorkloadAdolescentBacterial Typing TechniquesChildChild, PreschoolDiagnosis, DifferentialFemaleHealth Planning GuidelinesHumansIndiaInfantInfant, NewbornMale

Identifiers

PMID30933997
PMCPMC6443160
OpenAlexW2932261950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.